Back to News
Market Impact: 0.25
Mayne Pharma, Sun Pharma Settle IMVEXXY Patent Case, Generic Entry Set For 2032
Source: Nasdaq
Legal & LitigationPatents & Intellectual PropertyHealthcare & Biotech
Mayne Pharma announced that Sun Pharmaceutical Industries agreed to settle U.S. Paragraph IV patent litigation involving IMVEXXY and its FDA Orange Book-listed patents. The settlement reduces legal and intellectual-property uncertainty around the product, though financial terms and any impact on generic entry were not disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- UK Prime Minister Burnham says Iran 'played a part' in British air base incident
- US judge approves settlement allowing Paramount to acquire Warner Bros
- Why is Nidec stock plunging today?
- Nidec Corp shares slump after auditor declines to sign off on earnings
- US judge allows Paramount to close Warner Bros acquisition
- OpenAI is sued over rogue AI Hugging Face cyberattack